Injeksi virus hentikan pertumbuhan tumor pankreas dalam uji coba

Sebuah virus yang direkayasa secara genetik telah menghentikan pertumbuhan tumor pankreas pada tiga pasien dalam uji klinis tahap awal di Amerika Serikat. Hasil ini berasal dari studi keamanan yang dipimpin oleh para peneliti di University of Minnesota.

Pasien pertama menerima perawatan tersebut setahun yang lalu setelah didiagnosis dengan tumor berukuran 7 sentimeter yang terbatas pada pankreas. Dua pasien lainnya dirawat kemudian, dan ketiganya tetap hidup dengan kondisi penyakit yang stabil, menurut Masato Yamamoto, yang memimpin pengembangan terapi ini. Hanya sepersepuluh dari dosis yang direncanakan yang digunakan dalam tahap awal ini, namun tumor tidak menyebar atau membesar sejak injeksi dilakukan.

Artikel Terkait

Microscopic view of enhanced natural killer cells attacking cancer cells due to a drug developed by McGill researchers.
Gambar dihasilkan oleh AI

McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers

Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.

Researchers report that a single injection of a modified herpes virus draws immune cells deep into glioblastoma tumors, leading to longer survival in a clinical trial. The therapy, tested on 41 patients with recurrent brain cancer, activates T cells that persist and attack cancer cells. Findings were published in Cell.

Dilaporkan oleh AI

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Dilaporkan oleh AI

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak